Yesterday’s H1 results revealed a broadly flat revenue performance (+1.5% YoY) in spite of currency headwinds, weaker cosmeceuticals sales at Lansen and challenging trading at Haizi. The solid top line performance, mainly a result of strong pharmaceutical and plant extract sales, was mitigated at the EBIT level by higher sales & marketing investment. However, net profit showed strong YoY growth to $5.7m from $(1.9)m in H1 2016, driven by non-recurring income from the sale of shares in Starry by ....
31 Aug 2017
N+1 Singer - Cathay International Holdings Limited - H1: strong pharma & extract sales; Haizi and Fillderm weaker
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Cathay International Holdings Limited - H1: strong pharma & extract sales; Haizi and Fillderm weaker
- Published:
31 Aug 2017 -
Author:
Dr Jens Lindqvist -
Pages:
3
Yesterday’s H1 results revealed a broadly flat revenue performance (+1.5% YoY) in spite of currency headwinds, weaker cosmeceuticals sales at Lansen and challenging trading at Haizi. The solid top line performance, mainly a result of strong pharmaceutical and plant extract sales, was mitigated at the EBIT level by higher sales & marketing investment. However, net profit showed strong YoY growth to $5.7m from $(1.9)m in H1 2016, driven by non-recurring income from the sale of shares in Starry by ....